'Tdf' diaporamas de présentation

Understanding the unmet medical needs with current ART Francois Venter

Thanks: Polly Clayden, Francesca Conradie, Loyd Mulenga, Gary Maartens, Andrew Hill, David Ripin, Elli Katabira, Chris Duncombe, Nathan Ford, Marco Vitoria, WHO, Trip Gullik Industry: Gilead , Janssen, Viiv , Abbott, Merck, GSK. Understanding the unmet medical needs with current ART

528 views • 52 slides

Experience with first-line ARV regimens in Lusaka

Ministry of Health Zambia. University of Alabama at Birmingham. Experience with first-line ARV regimens in Lusaka. Jeff Stringer, MD Professor, Obstetrics and Gynecology, UAB Director, Centre for Infectious Disease Research in Zambia. The University of Alabama at Birmingham.

525 views • 43 slides

Antiretroviral Therapy: A Case-Based Panel Discussion (Part II)

Antiretroviral Therapy: A Case-Based Panel Discussion (Part II). Eric S. Daar , MD Michael S. Saag , MD. From MS Saag , MD and ES Daar , MD at San Francisco, CA: March 29,2013, IAS-USA. Switch for Toxicity. Eric S. Daar , MD Professor of Medicine David Geffen School of Medicine at UCLA.

518 views • 41 slides

Conference Call Line: 1-800 -920-7487 Participant Code: 9982883

Conference Call Line: 1-800 -920-7487 Participant Code: 9982883 Please type your name into the chat box to confirm your attendance. Visit us at www.med.unc.edu / ncaidstraining.

385 views • 38 slides

Delivering Value in a Target-Date Dominated World

Delivering Value in a Target-Date Dominated World. Dick Darian Head of DC Advisor Sales, BlackRock Marcia Wagner Managing Partner, The Wagner Law Group. 11/13/13. By 2020 Target Date Funds Are Projected to Grow To $3.7 Trillion.

319 views • 31 slides

Through-Delta Facility & Delta Cross-Channel Projects

Through-Delta Facility & Delta Cross-Channel Projects. TDF DCC Re-operation Sean Bagheban. Status of the TDF/DCC Projects. Hydrodynamics & Water Quality Modeling by RMA 2006 & 2007 USGS Experiments Salmon Behavior Secondary Circulation

383 views • 27 slides

320 views • 22 slides

Presented by Marcia S. Wagner, Esq.

Target Date Funds and Plan Sponsor Responsibilities Live ByAllAccounts Webinar - May 16, 10AM EST. Presented by Marcia S. Wagner, Esq. About ByAllAccounts.

281 views • 17 slides

Presented by Marcia S. Wagner, Esq.

Target Date Funds and Plan Sponsor Responsibilities Live ByAllAccounts Webinar - May 16, 10AM EST. Presented by Marcia S. Wagner, Esq. About ByAllAccounts.

174 views • 17 slides

Market Information Initiative - Boston University School of Medicine

Transitioning from stavudine (d4T) to tenofovir (TDF) and zidovudine (ZDV) in low and middle income countries. Market Information Initiative - Boston University School of Medicine International AIDS Society Conference 2012. Study objectives.

241 views • 16 slides

CR EACS Cologne

CR EACS Cologne. 11-14 Novembre 2009. LBPE9.7/8 - Prevalence of proximal renal tubular dysfunction (PRTD) and associated factors in HIV-infected patients, ANRS CO3 Aquitaine cohort. Cohorte Aquitaine Suivi prospectif 187 hommes/63 femmes Dysfonction tubulaire: 6% Co-infection B Kaletra

248 views • 13 slides

Target Date Funds and P lan S ponsor Responsibilities

Target Date Funds and P lan S ponsor Responsibilities. Marcia S. Wagner, Esq. Background on Target Date Funds. Popular default investment vehicle for 401(k) plans. Typically, formed as open-end investment companies registered under the Inv. Co. Act.

194 views • 12 slides

Washington, D.C. July 23, 2012

TUAB0201. HPTN 057. Tenofovir Disoproxil Fumarate (TDF) Pharmacokinetics (PK) with Daily Dosing in the First Week of Life (HPTN 057)

255 views • 12 slides

LAM

A. Pt-1. Pt-2. *. *. LAM-ADV. LAM-ADV. ?. *. LAM. * LAM-TDF. ? LAM; * LAM-TDF. Pt-3. Pt-4. ?. ETV-TDF. *. *. LAM-ADV. LAM-ADV. LAM. LAM. * ETV-ADV; ? ETV-TDF. * ETV. Pt-6. Pt-5. *. LAM-ADV. ETV-TDF. LAM. LAM-ADV. * LAM-TDF. Pt-7. Pt-8. ETV-TDF. ETV. ETV-ADV.

226 views • 10 slides

Comparison of NNRTI vs NNRTI

109 views • 10 slides

Comparison of NRTI combinations

Comparison of NRTI combinations. ZDV/3TC vs TDF + FTC Study 934 ABC/3TC vs TDF/FTC HEAT Study ACTG A5202 Study ASSERT Study TAF vs TDF Study 292-0102. Study 934: zidovudine/lamivudine fixed dose combination vs tenofovir + emtricitabine. Study 934. Design. Randomisation* 1 : 1

337 views • 8 slides